Evaluation Of A Virtual Cardiology Program To Improve Outcomes After Acute Decompensated Heart Failure

Prior treatment

• Optimized or nearly optimized on evidence-based medical therapies for HF as determined by local investigator
• Chronic use of intravenous inotropic medications including milrinone, dobutamine, or dopamine
• History of prior heart transplant or currently listed for heart transplant
• Currently receiving hospice care
• Chronically resides in an assisted living or skilled nursing facility where medications are managed by facility personnel

Other illness

• Terminal illness other than HF with a life expectancy of \<1 year as determined by the enrolling clinician-investigator

Lab values

• eGFR of \<20 mL/min/1.73m2 ongoing chronic dialysis at screening. The eGFR should be estimated using the 2021 Chronic Kidney Disease Epidemiology Collaboration (2021 CKD-EPI) creatinine equation.

Other

• Current pregnancy
• Current left ventricular assist device or planned left ventricular assist device in the next 6 months

• Age ≥18 years of age
• Acute decompensated HF as a primary cause of hospitalization. Hospitalizations for acute decompensated HF will be determined by local clinician-investigators but should include findings of acute HF (i.e., symptoms, signs, and/or laboratory/imaging abnormalities) and treatments aimed at acute HF (e.g., intravenous diuretics, vasodilators, or inotropes). Participants with a new diagnosis of HF may be enrolled. The enrollment will be monitored to ensure no more than 2/3 of the total cohort has new-onset HF.
• Fluent in written and spoken English